Merkel, Martin http://orcid.org/0000-0002-2850-5110
Berg, Daniela
Brüggemann, Norbert
Classen, Joseph
Mainka, Tina
Zittel, Simone
Muntau, Ania C.
Funding for this research was provided by:
BioMarin Deutschland GmbH and BioMarin Pharmaceutical Inc.
Article History
Received: 22 December 2022
Revised: 31 March 2023
Accepted: 1 April 2023
First Online: 20 April 2023
Declarations
:
: MM received consulting payments and/or speaker fees from Sanofi, Amgen, Lilly, MSD, Berlin-Chemie, Novartis, Astra, BioMarin, Akcea, Daiichi-Sankyo, Gilead, Novo and Pfizer. DB had no relevant conflicts of interest to declare. NB received consulting payments from Abbott, Abbvie, Biogen, BioMarin, BridgeBio, Centogene and Zambon and participated as investigator in clinical trials for Bial and Biogen. JC received consulting payments from BioMarin. TM received consulting payments and speaker fees from BioMarin and STADApharm GmbH, participated as investigator in clinical trials for Abide Therapeutics and Roche and received royalties from Elsevier Urban & Fisher. SZ received consulting payments from BioMarin, participated as investigator in clinical trials for Centogene and received speaker fees from Merz Pharmaceutics. ACM received consulting fees, research grants and speaker fees from BioMarin and participated as investigator in clinical trials for BioMarin and PTC.